Complete Response to Chemotherapy against the Recurrence of Neuroendocrine Carcinoma of the Breast in the Anterior Mediastinal Lymph Nodes of a Patient on Hemodialysis: A Case Report

Chikuie, Emi; Yanagawa, Senichiro; Tanji, Hidehiro; Kodama, Shinya; Takeshima, Yukio; Sumimoto, Kazuo

doi:10.1159/000497479

Cited by 3 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Escape is frequent after a few months, but the neuroendocrine component can be controlled by anthracycline-based therapy (35). However, a complete response, with a disease free period of thirty-six months after chemotherapy, was recently observed in one patient treated with six FEC 100 (5-fluorouracil, epirubicin, and cyclophosphamide) cycles followed by docetaxel (60). Another rare case of HER-2 positive NECB was treated with trastuzumab with a reported disease free period of 9 years (62).…”

Section: Therapymentioning

confidence: 99%

Primary Neuroendocrine Neoplasms of the Breast: Still Open Issues

et al. 2021

View full text Add to dashboard Cite

Neuroendocrine breast tumors represent a rare subtype of breast cancer, accounting for less than 1% of all neuroendocrine neoplasms. Starting from their pathology definition, and going through their prevalence, prognosis and treatment, our knowledge is still really uncertain. In the present short review of the medical literature on this topic, we have evaluated in details their epidemiology, risk factors, pathogenesis, pathology, clinical presentation, radiographic aspects, prognosis, and therapy. We have thus been able to identify a number of open issues regarding primary neuroendocrine neoplasms of the breast that need to be clarified. Our ultimate aim was actually to try to understand whether neuroendocrine neoplasms of the breast can be considered a definite clinical entity and if neuroendocrine differentiation of breast tumors has a really clinical relevance.

show abstract

Section: Therapymentioning

confidence: 99%

Primary Neuroendocrine Neoplasms of the Breast: Still Open Issues

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Neuroendocrine components can be controlled by anthracyclines 27 . Patients treated with chemotherapy reportedly had a DFS of ≤36 months 28 . However, patients who received chemotherapy had shorter OS and DFS than those who did not 12 .…”

Section: Discussionmentioning

confidence: 99%

“…This may be related to cultural differences. 27 , 28 In addition, Chinese women have relatively small breasts and may not always be eligible for breast‐conserving surgery. The proportion of patients with NEBCs treated with radiation therapy was lower in China than in the US.…”

Section: Discussionmentioning

confidence: 99%

“…27 Patients treated with chemotherapy reportedly had a DFS of ≤36 months. 28 However, patients who received chemotherapy had shorter OS and DFS than those who did not. 12 Many studies have shown that NETs often exhibit overexpression of growth inhibitors.…”

Section: Discussionmentioning

confidence: 99%

“…The Chinese patients were more likely to receive mastectomies, whereas the US patients were more likely to receive lumpectomies. This may be related to cultural differences 27,28 . In addition, Chinese women have relatively small breasts and may not always be eligible for breast‐conserving surgery.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic factors of primary neuroendocrine breast cancer: A population‐based study

Wang

Liu

et al. 2022

Cancer Medicine

View full text Add to dashboard Cite

Background Primary neuroendocrine breast carcinomas (NEBCs) are an extremely rare and underrecognized subtype of mammalian carcinoma. The prognostic factors for NEBCs remain controversial. Methods In this multicenter retrospective study, the prognostic factors for patients with primary NEBCs who underwent surgery and had a pathologically confirmed diagnosis of neuroendocrine carcinoma in China and the United States were examined. The endpoints were disease‐free survival (DFS) and overall survival (OS). Results A total of 51 Chinese patients and 98 US patients were included. In the Chinese cohort, tumor grade and Ki‐67 levels were prognostic factors for DFS in univariate analysis (hazard ratio [HR] = 5.11 [1.67–15.60], p = 0.004; HR = 57.70 [6.36–523.40], p < 0.001, respectively) and multivariate analysis (HR = 100.52 [1.33–7570.21], p = 0.037; HR = 31.47 [1.05–945.82], p = 0.047, respectively). In the US cohort, age was an important prognostic factor for OS in univariate analysis (HR = 1.09 [1.04–1.15], p = 0.001). The random effects model for the combined cohorts revealed age and positive expression of estrogen receptor (ER) as potential prognostic factors for OS (HR = 1.08 [1.01–1.14], p = 0.015; HR = 0.10 [0.02–0.44], p = 0.003, respectively). Conclusions Tumor grade and Ki‐67 levels are important prognostic factors for DFS of patients with primary NEBCs. Age and ER status are important prognostic factors for OS of patients with primary NEBCs.

show abstract

Neuroendocrine Neoplasms of the Breast: Current Insights and Future Directions

Jiang,

Pan,

Lang

2024

Cancer Reports

View full text Add to dashboard Cite

BackgroundThe breast neuroendocrine neoplasms (NENs) represent a heterogeneous group of tumors and account for less than 1% of all NENs. The 5th edition of the WHO Classification of Breast Tumors in 2019 introduced a more stringent definition for breast NENs including neuroendocrine tumors (NETs) (G1, G2) and neuroendocrine carcinomas (NECs) (small cell carcinoma, large cell neuroendocrine carcinoma). While the diagnostic criteria and treatment of breast NENs still have some unsolved issues.ObjectiveWe aim to discuss the diagnosis, treatment progress, existing problems, and future development direction of breast NENs.MethodsWe provide a comprehensive review and evaluation of the diagnostic criteria, pathological features, utilization of immunohistochemical markers, molecular characteristics, pathogenesis, clinical significance, treatment options for breast NENs.Results(1) Under the new definition, "pure" breast NENs are extremely rare. (2) Breast NETs are graded according to Nottingham grading System. Grading criteria utilized in other systems for NENs, such as mitotic count, ki67 proliferation index, and necrosis, have not been applied to breast NENs. (3) The WHO has not yet acknowledged the existence of NET G3 clearly. (4) The expression of NE markers may differ in breast NECs. (5) The treatment of breast NENs is still based on IBCs‐NST, and without any difference from invasive carcinoma with NE features. (6) The prognosis of breast NENs remains unclear, while the prognosis for NECs is significantly poorer than invasive breast carcinomas of no special type (IBCs‐NST) has been confirmed.ConclusionStrict adherence to criteria is the key to correctly diagnose breast NENs with the exclusion of metastasis from other sites. Further exploration is required to determine the tissue origin of breast NENs and understand the pathogenesis. Efforts are still needed to establish unified diagnostic criteria and a unique diagnosis and treatment consensus for breast NENs.

show abstract

Complete Response to Chemotherapy against the Recurrence of Neuroendocrine Carcinoma of the Breast in the Anterior Mediastinal Lymph Nodes of a Patient on Hemodialysis: A Case Report

Cited by 3 publications

References 10 publications

Primary Neuroendocrine Neoplasms of the Breast: Still Open Issues

Primary Neuroendocrine Neoplasms of the Breast: Still Open Issues

Prognostic factors of primary neuroendocrine breast cancer: A population‐based study

Neuroendocrine Neoplasms of the Breast: Current Insights and Future Directions

Contact Info

Product

Resources

About